company background image
4128

Microbio TPEX:4128 Stock Report

Last Price

NT$69.20

Market Cap

NT$35.4b

7D

7.3%

1Y

8.3%

Updated

27 Nov, 2022

Data

Company Financials
4128 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends0/6

4128 Stock Overview

Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan.

Microbio Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Microbio
Historical stock prices
Current Share PriceNT$69.20
52 Week HighNT$81.30
52 Week LowNT$46.44
Beta1.46
1 Month Change28.86%
3 Month Change-5.85%
1 Year Change8.35%
3 Year Change486.56%
5 Year Change284.72%
Change since IPO528.79%

Recent News & Updates

Recent updates

Should You Use Microbio's (GTSM:4128) Statutory Earnings To Analyse It?

Jan 04
Should You Use Microbio's (GTSM:4128) Statutory Earnings To Analyse It?

Shareholder Returns

4128TW Personal ProductsTW Market
7D7.3%3.1%1.7%
1Y8.3%-13.4%-15.3%

Return vs Industry: 4128 exceeded the TW Personal Products industry which returned -13.4% over the past year.

Return vs Market: 4128 exceeded the TW Market which returned -15.3% over the past year.

Price Volatility

Is 4128's price volatile compared to industry and market?
4128 volatility
4128 Average Weekly Movement7.2%
Personal Products Industry Average Movement4.8%
Market Average Movement4.9%
10% most volatile stocks in TW Market8.2%
10% least volatile stocks in TW Market2.4%

Stable Share Price: 4128 is more volatile than 75% of TW stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 4128's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of TW stocks.

About the Company

FoundedEmployeesCEOWebsite
2000n/aHsien-Shou Kuohttps://www.microbio.com.tw

Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for ameliorating fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia and menstrual discomfort. Its pre-clinical stage products include SNA-03 and SNA-07 for cancer immune therapy; SNP-630 to treat non-alcoholic steatohepatitis; FB918 for the treatment of non-allergic eosinophilic asthma; and SNS812 for Cov-flu.

Microbio Co., Ltd. Fundamentals Summary

How do Microbio's earnings and revenue compare to its market cap?
4128 fundamental statistics
Market CapNT$35.37b
Earnings (TTM)NT$1.05b
Revenue (TTM)NT$1.71b

33.7x

P/E Ratio

20.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
4128 income statement (TTM)
RevenueNT$1.71b
Cost of RevenueNT$998.89m
Gross ProfitNT$716.07m
Other Expenses-NT$334.21m
EarningsNT$1.05b

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)2.05
Gross Margin41.75%
Net Profit Margin61.24%
Debt/Equity Ratio0%

How did 4128 perform over the long term?

See historical performance and comparison

Dividends

0.05%

Current Dividend Yield

2%

Payout Ratio